References
- Kim DW, Banavali SD, Bunvorate U, Goh YT, Ganly P, Huang H, et al.. Chronic myeloid leukemia in the Asia Pacific region: current practice, challenges and opportunities in the targeted therapy era. Leuk Res. 2010;34:1459–71.
- Au WY, Caguioa PB, Chuah C, Hsu SC, Jootar S, Kim DW, et al.. Chronic myeloid leukemia in Asia. Int J Hematol. 2009;89:14–23.
- Zhao Y, Liu L, Wang Y, Wu G, Lai X, Cao W, et al.. Efficacy and Prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population. Int J Hematol. 2009;89:445–51.
- Rajappa S, Varadpande L, Paul T, Jacob R, Digumarti R. Imatinib mesylate in early chronic phase chronic myeloid leukemia: Experience from a developing country. Leuk Lymph. 2008;49:554–8.
- Aziz Z, Iqbal J, Akram M, Saeed S. Treatment of chronic myeloid leukemia in the imatinib era. Perspective from a developing country. Cancer. 2007;109:1138–45.
- Kanda Y, Okamoto S, Tauchi T, Kizaki M, Inokuchi K, Yabe M, et al.. Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter? Am J Hematol. 2008;83:835–9.
- Nagai T, Takeuchi J, Dobashi N, Kanakura Y, Taniguchi S, Ezaki K, et al.. Imatinib for newly diagnosed chronic-phase chronic myeloid leukemia: Results of a prospective study in Japan. Int J Hematol. 2010;92:111–7.
- O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al.. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. New Engl J Med. 2003;248:994–1004.
- Lahaye T, Riehm B, Berger U. Response and resistance in 300 patients with bcr-abl positive leukemias treated with imatinib in a single center: 4·5 years follow up. Cancer. 2005;103:1659–69.
- Cortes JE, Talpaz M, O’Brien S, Faderl S, Garcia-Manero G, Ferrajoli A, et al.. Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal. Cancer. 2006;106(6):1306–15.